[go: up one dir, main page]

WO2001096372A3 - Zinc transporters proteins and their use in medicinal preparations - Google Patents

Zinc transporters proteins and their use in medicinal preparations Download PDF

Info

Publication number
WO2001096372A3
WO2001096372A3 PCT/GB2001/002597 GB0102597W WO0196372A3 WO 2001096372 A3 WO2001096372 A3 WO 2001096372A3 GB 0102597 W GB0102597 W GB 0102597W WO 0196372 A3 WO0196372 A3 WO 0196372A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
zinc
methods
family
disorders
Prior art date
Application number
PCT/GB2001/002597
Other languages
French (fr)
Other versions
WO2001096372A2 (en
Inventor
Kathryn Mary Taylor
Helen Elizabeth Morgan
Robert Ian Nicholson
Original Assignee
Univ Cardiff
Kathryn Mary Taylor
Helen Elizabeth Morgan
Robert Ian Nicholson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014411A external-priority patent/GB0014411D0/en
Priority claimed from GB0014493A external-priority patent/GB0014493D0/en
Application filed by Univ Cardiff, Kathryn Mary Taylor, Helen Elizabeth Morgan, Robert Ian Nicholson filed Critical Univ Cardiff
Priority to AU2001264099A priority Critical patent/AU2001264099A1/en
Publication of WO2001096372A2 publication Critical patent/WO2001096372A2/en
Publication of WO2001096372A3 publication Critical patent/WO2001096372A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A family of protein sequences has been identified, the function of which is to regulate zinc levels in cells. Methods of treatment and diagnosis of diseases selected from those involving disorders of zinc homeostasis are provided, the methods comprising the administration of therapeutically effective amounts of one or more polypeptides comprising the consensus regions of the proteins, or homologues thereof, or antibodies generated against the regions or the proteins. The particular diseases concerned may include neurodegenerative disorders and oestrogen responsive metastatic breast cancer. Also provided are methods for the selection of test compounds for use in the treatment of zinc-homeostasis related disorders, and recombinant proteins containing one or more of the consensus sequences of the family of proteins.
PCT/GB2001/002597 2000-06-13 2001-06-13 Zinc transporters proteins and their use in medicinal preparations WO2001096372A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001264099A AU2001264099A1 (en) 2000-06-13 2001-06-13 Zinc transporters

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0014411A GB0014411D0 (en) 2000-06-13 2000-06-13 Zinc transporters
GB0014411.3 2000-06-13
GB0014493.1 2000-06-14
GB0014493A GB0014493D0 (en) 2000-06-14 2000-06-14 Zine transporters
US21634900P 2000-07-05 2000-07-05
US60/216,349 2000-07-05

Publications (2)

Publication Number Publication Date
WO2001096372A2 WO2001096372A2 (en) 2001-12-20
WO2001096372A3 true WO2001096372A3 (en) 2002-05-16

Family

ID=27255758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/002597 WO2001096372A2 (en) 2000-06-13 2001-06-13 Zinc transporters proteins and their use in medicinal preparations

Country Status (2)

Country Link
AU (1) AU2001264099A1 (en)
WO (1) WO2001096372A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48959E1 (en) 2010-12-06 2022-03-08 Seagen Inc. Humanized antibodies to LIV-1 and use of same to treat cancer
US11325980B2 (en) 2016-03-15 2022-05-10 Seagen Inc. Combination therapy using a LIV1-ADC and a chemotherapeutic

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
EP1578364A4 (en) * 2002-09-16 2011-06-08 Genentech Inc Compositions and methods for the treatmentof immune related diseases
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
JPWO2005063301A1 (en) * 2003-12-26 2007-07-19 平野　俊夫 EMT inducer
US7916304B2 (en) 2006-12-21 2011-03-29 Howard Hughes Medical Institute Systems and methods for 3-dimensional interferometric microscopy
US9505825B2 (en) 2013-05-15 2016-11-29 Syracuse University Methods and systems for zinc delivery using intrinsic factor or haptocorrin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE ENTREZ NUCLEOTIDE NCBI; 8 February 2001 (2001-02-08), GREEN, C ET AL.: "Human Breast Cancer, estrogen regulated LIV-1 protein (LIV-1) mRNA, complete cds.", XP002175107 *
DATABASE ENTREZ NULCEOTIDE NCBI; 6 April 1996 (1996-04-06), GREEN, C ET AL.: "Human Breast Cancer, estrogen regulated LIV-1 protein (LIV-1) mRNA, partial cds.", XP002175106 *
TAYLOR K M ET AL: "THE LIV-1 GENE, IMPLICATED IN METASTATIC BREAST CANCER, CODES FOR A HISTIDINE-RICH TRANSMEMBRANE PROTEIN", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 80, no. SUPPL 2, 11 July 1999 (1999-07-11), pages 24, XP001013344, ISSN: 0007-0920 *
TAYLOR K M: "LIV-1 BREAST CANCER PROTEIN BELONGS TO NEW FAMILY OF HISTIDINE-RICHMEMBRANE PROTEINS WITH POTENTIAL TO CONTROL INTRACELLULAR ZN2+ HOMEOSTASIS", IUBMB LIFE, TAYLOR AND FRANCIS, LONDON,, GB, vol. 49, no. 4, April 2000 (2000-04-01), pages 249 - 253, XP001012651, ISSN: 1521-6543 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48959E1 (en) 2010-12-06 2022-03-08 Seagen Inc. Humanized antibodies to LIV-1 and use of same to treat cancer
US11325980B2 (en) 2016-03-15 2022-05-10 Seagen Inc. Combination therapy using a LIV1-ADC and a chemotherapeutic

Also Published As

Publication number Publication date
WO2001096372A2 (en) 2001-12-20
AU2001264099A1 (en) 2001-12-24

Similar Documents

Publication Publication Date Title
Blesch et al. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA
Eulitz et al. Immunoglobulin heavy-chain-associated amyloidosis.
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
ES2260756T3 (en) PROTEIN AND ALLERGEN PEPTIDES OF DOG CASPA AND ITS USES.
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
ATE283289T1 (en) MONOCLONAL ANTIBODIES, ANTIGENS AND DIAGNOSIS AND THERAPY OF MALIGNANT DISEASES
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
HRP20030547A8 (en) HUMANIZED BETA-RECOGNIZING ANTIBODIES AMILOID PEPTID
WO2002059604A8 (en) Diagnosis and treatment of multiple sclerosis
ATE132197T1 (en) MONOCLONAL ANTIBODIES
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
IL176076A0 (en) Ligands,including antibodies showing, reactivity against endocrine cells
Clayman et al. Isolation of the target antigen of human anti-tubular basement membrane antibody-associated interstitial nephritis.
AU9291198A (en) Apoptosis-related compounds and their use
WO2001096372A3 (en) Zinc transporters proteins and their use in medicinal preparations
WO1997048804A3 (en) Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses
WO2001002556A3 (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
CN101365469A (en) Methods of treating obesity using enterostatin
CA2123694A1 (en) Peptides and antibodies for treatment of rheumatoid arthritis
RU2446174C2 (en) Peptide with antiproliferative activity and pharmaceutical composition for treating proliferative diseases
WO2001083781A3 (en) 14094, a novel human trypsin family member and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP